| Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia F Nadeu, J Delgado, C Royo, T Baumann, T Stankovic, M Pinyol, P Jares, ... Blood 127 (17), 2122-2130, 2016 | 363 | 2016 |
| MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia C Jiménez, E Sebastián, MC Chillón, P Giraldo, JM Hernández, ... Leukemia 27 (8), 1722-1728, 2013 | 300 | 2013 |
| Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism … ME Sarasquete, R García-Sanz, L Marín, M Alcoceba, MC Chillón, ... Blood 112 (7), 2709-2712, 2008 | 272 | 2008 |
| Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry N Puig, ME Sarasquete, A Balanzategui, J Martinez, B Paiva, H Garcia, ... Leukemia 28 (2), 391-397, 2014 | 205 | 2014 |
| Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation EM Villaron, J Almeida, N López-Holgado, M Alcoceba, ... haematologica 89 (12), 1421-1427, 2004 | 188 | 2004 |
| Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets K Karube, A Enjuanes, I Dlouhy, P Jares, D Martin-Garcia, F Nadeu, ... Leukemia, 2017 | 181 | 2017 |
| Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia CM Santamaría, MC Chillón, R García-Sanz, C Pérez, MD Caballero, ... Blood 114 (1), 148-152, 2009 | 131 | 2009 |
| The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation T Lion, F Watzinger, S Preuner, H Kreyenberg, M Tilanus, R de Weger, ... Leukemia 26 (8), 1821-1828, 2012 | 117 | 2012 |
| Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia F Nadeu, G Clot, J Delgado, D Martín-García, T Baumann, I Salaverria, ... Leukemia, 2017 | 108 | 2017 |
| Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis M Federico, MDC Barrigón, L Marcheselli, V Tarantino, M Manni, ... The Lancet Haematology 5 (8), e359-e367, 2018 | 104 | 2018 |
| Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma A Medina, N Puig, J Flores-Montero, C Jimenez, ME Sarasquete, ... Blood cancer journal 10 (10), 1-10, 2020 | 86 | 2020 |
| CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival MJ Moreno, R Bosch, R Dieguez‐Gonzalez, S Novelli, A Mozos, ... The Journal of pathology 235 (3), 445-455, 2015 | 82 | 2015 |
| Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB … E Sebastián, M Alcoceba, A Balanzategui, L Marín, S Montes-Moreno, ... The American journal of pathology 181 (5), 1879-1888, 2012 | 81 | 2012 |
| Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group S Alonso‐Álvarez, L Magnano, M Alcoceba, M Andrade‐Campos, ... British journal of haematology 178 (5), 699-708, 2017 | 77 | 2017 |
| Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström’s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance P Martín-Jiménez, R García-Sanz, A Balanzategui, M Alcoceba, E Ocio, ... haematologica 92 (5), 635-642, 2007 | 71 | 2007 |
| Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia MC Chillón, MT Gómez-Casares, CE López-Jorge, C Rodriguez-Medina, ... Leukemia 26 (11), 2360-2366, 2012 | 69 | 2012 |
| High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics CM Santamaría, MC Chillón, R García-Sanz, C Pérez, MD Caballero, ... Leukemia research 33 (12), 1706-1709, 2009 | 68 | 2009 |
| The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia C Santamaría, MC Chillón, R García-Sanz, A Balanzategui, ... haematologica 93 (12), 1797-1805, 2008 | 66 | 2008 |
| Detection of early seeding of Richter transformation in chronic lymphocytic leukemia F Nadeu, R Royo, R Massoni-Badosa, H Playa-Albinyana, B Garcia-Torre, ... Nature medicine 28 (8), 1662-1671, 2022 | 65 | 2022 |
| BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML) C Santamaría, MC Chillón, R García-Sanz, C Pérez, MD Caballero, ... Annals of hematology 89 (5), 453-458, 2010 | 64 | 2010 |
